These data raise the concern that the use of GM-CSF as an adjuvant or as a treatment agent might be harmful because GM-CSF can impair the vaccine-induced or anti-tumor immune responses under conditions that remain unclear. The gene discussed is CSF2; the disease is neoplasm.